ATE6937T1 - Hybridprotein gegen geschwuelste und verfahren zu seiner herstellung. - Google Patents

Hybridprotein gegen geschwuelste und verfahren zu seiner herstellung.

Info

Publication number
ATE6937T1
ATE6937T1 AT80301111T AT80301111T ATE6937T1 AT E6937 T1 ATE6937 T1 AT E6937T1 AT 80301111 T AT80301111 T AT 80301111T AT 80301111 T AT80301111 T AT 80301111T AT E6937 T1 ATE6937 T1 AT E6937T1
Authority
AT
Austria
Prior art keywords
moiety
sub
fragment
antitumor
indicates
Prior art date
Application number
AT80301111T
Other languages
English (en)
Inventor
Yasuhiko Masuho
Takeshi Hara
Teruhisa Noguchi
Original Assignee
Teijin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Limited filed Critical Teijin Limited
Application granted granted Critical
Publication of ATE6937T1 publication Critical patent/ATE6937T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061Blood cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6829Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT80301111T 1979-04-09 1980-04-08 Hybridprotein gegen geschwuelste und verfahren zu seiner herstellung. ATE6937T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4191979A JPS55136235A (en) 1979-04-09 1979-04-09 Antitumor protein complex and its preparation
EP80301111A EP0017507B1 (de) 1979-04-09 1980-04-08 Hybridprotein gegen Geschwülste und Verfahren zu seiner Herstellung

Publications (1)

Publication Number Publication Date
ATE6937T1 true ATE6937T1 (de) 1984-04-15

Family

ID=12621650

Family Applications (1)

Application Number Title Priority Date Filing Date
AT80301111T ATE6937T1 (de) 1979-04-09 1980-04-08 Hybridprotein gegen geschwuelste und verfahren zu seiner herstellung.

Country Status (9)

Country Link
US (1) US4638049A (de)
EP (1) EP0017507B1 (de)
JP (1) JPS55136235A (de)
AT (1) ATE6937T1 (de)
AU (1) AU533861B2 (de)
DE (1) DE3067313D1 (de)
FI (1) FI801108A (de)
HU (1) HU184736B (de)
IL (1) IL59727A (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5616417A (en) * 1979-07-19 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
JPS5686121A (en) * 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
EP0044167A3 (de) * 1980-07-14 1982-04-21 The Regents Of The University Of California Durch einen Antikörper gerichtetes zytotoxisches Mittel
JPS57106626A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
JPS57106625A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
FI820020L (fi) * 1981-01-12 1982-07-13 Lilly Industries Ltd Immunoglobulinkonjugater
SE8102194L (sv) * 1981-04-06 1982-10-07 Pharmacia Ab Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
JPS63290824A (ja) * 1987-05-22 1988-11-28 Sumitomo Chem Co Ltd ウイルス感染症治療剤
US5241078A (en) * 1988-06-14 1993-08-31 Cetus Oncology Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
CA2082265A1 (en) * 1990-05-07 1991-11-08 Chien-Hsing Chang Method for radiolabeling monovalent antibody fragments
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
WO2007106435A2 (en) * 2006-03-10 2007-09-20 University Of California Cleavable vaccines compositions and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201770A (en) * 1973-05-07 1980-05-06 The Ohio State University Antigenic modification of polypeptides
US4160018A (en) * 1973-06-25 1979-07-03 Bjorklund Knut B Stabilized cancer associated polypeptide antigen and preparation thereof
DE2456224A1 (de) * 1974-11-28 1976-08-12 Karl Dr Med Theurer Verwendung von nativen antikoerpern oder von antikoerper-fragmenten mit kovalent gebundenen oder konjugierten zytostatisch und/bzw. oder zytotoxisch wirkenden substanzen fuer die krebstherapie
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
US4174385A (en) * 1976-10-08 1979-11-13 Robert Reid Method of identification of surface proteins of cancer cells, clinical test and method of immunization
DE2862449D1 (en) * 1977-08-22 1984-11-22 Nat Res Dev Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them
JPS54145655A (en) * 1978-05-06 1979-11-14 Asahi Chem Ind Co Ltd Imidate derivative and its salt

Also Published As

Publication number Publication date
HU184736B (en) 1984-10-29
EP0017507A2 (de) 1980-10-15
DE3067313D1 (en) 1984-05-10
AU533861B2 (en) 1983-12-15
JPH02328B2 (de) 1990-01-08
IL59727A (en) 1983-03-31
JPS55136235A (en) 1980-10-23
US4638049A (en) 1987-01-20
EP0017507A3 (en) 1981-08-05
FI801108A (fi) 1980-10-10
AU5722880A (en) 1980-10-16
IL59727A0 (en) 1980-06-30
EP0017507B1 (de) 1984-04-04

Similar Documents

Publication Publication Date Title
ATE7574T1 (de) Antitumor-proteinhybrid und verfahren zu seiner herstellung.
ATE6937T1 (de) Hybridprotein gegen geschwuelste und verfahren zu seiner herstellung.
ATE14023T1 (de) Einen monoklonalen antikoerper produzierende hybridzellinie, antikoerper und verfahren zu seiner herstellung, diesen antikoerper enthaltende therapeutische zusammensetzung und deren diagnostische und therapeutische verwendungen.
GB1520522A (en) 16-methyleneprostaglandins
FR2354327A1 (fr) Diglycidyl hydantoines et leurs applications comme matieres resineuses
JPS55149331A (en) Modifier for synthetic resin
BG35746A3 (en) Method for preparing 1- cyclohexenylmethylpyrolidines
JPS5616417A (en) Antitumor protein complex and its preparation
FI830397A0 (fi) Foerfarande foer framstaellning av imidazolidinderivat
FR2514006B1 (de)
ES478706A1 (es) Un metodo para producir un compuesto desmetilmaitansinoide.
YU25699A (sh) Novi derivati eritromicina, postupak za njihovu izradu i njihova primena
FR2356700A1 (fr) Pigments bis-azomethiniques metalliferes complexes
GB1524678A (en) Organosilicon compounds
GB1512179A (en) Thionobenzenephosphonic acid 0,0-diesters and their use as insecticides and acaricides
ES8301493A1 (es) Procedimiento para preparar polieteres sililados
GB1482388A (en) Method of producing 6-beta-amidinopenicillanic acid derivatives
GB1529463A (en) Pharmaceutical compositions
BG36200A3 (en) Method for preparing vinblastine- 3- (2- chlorethyl)- carboxymides
IT7849988A0 (it) Pero procedimento per produrre ghise in pani di composizione controllata apartire da minerali ferrosi di recu
ES486995A1 (es) Un procedimiento para la preparacion de una b-lactama
DE3468871D1 (de) Pesticidal nitromethylene derivates
JPS5473785A (en) 2-alkyl-4-trimethyl-5-fluorouracil
TH14773A (th) อนุพันธ์ของอีริโธรมัยซิน
ES403886A1 (es) Procedimiento de preparacion de amidas del acido (trimetoxi-3,4,5)cinemico.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties